UBE2C KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 2.
Images
Key facts
- Cell type
HeLa
- Species or organism
Human
- Tissue
Cervix
- Knockout validation
Sanger Sequencing, Western blot
- Mutation description
Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 2.
Alternative names
Cyclin selective ubiquitin carrier protein, Mitotic specific ubiquitin conjugating enzyme, UBCH 10, UBE2C_HUMAN, Ubiquitin carrier protein C, Ubiquitin carrier protein E2 C, Ubiquitin-conjugating enzyme E2 C, Ubiquitin-protein ligase C, dJ447F3.2
What's included?
Recommended products
UBE2C KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 2.
Key facts
- Cell type
HeLa
- Species or organism
Human
- Tissue
Cervix
- Knockout validation
Sanger Sequencing, Western blot
- Mutation description
Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 2.
- Disease
Adenocarcinoma
- Concentration
Properties
- Gene name
UBE2C
- Gene editing type
Knockout
- Gene editing method
CRISPR technology
- Knockout validation
Sanger Sequencing, Western blot
- Zygosity
Homozygous
Quality control
- STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
EU: 2 US: 2
- Adherent/suspension
Adherent
- Gender
Female
Storage
- Shipped at conditions
Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
-20°C
- Appropriate long-term storage conditions
-20°C
Notes
Knockout cell lysate achieved by CRISPR/Cas9.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
Supplementary info
This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
UBE2C also known as ubiquitin-conjugating enzyme E2C or UBCH10 is an enzyme that plays a role in the ubiquitination process. Its molecular mass is approximately 20 kDa. UBE2C is an E2 ubiquitin-conjugating enzyme actively involved in marking proteins for degradation through the ubiquitin-proteasome system. It facilitates the transfer of ubiquitin to target proteins cooperating with E3 ligases. UBE2C shows expression in various tissues with high levels observed in proliferating cells such as those found in tumors.
- Biological function summary
UBE2C is involved in cell cycle regulation by targeting specific proteins for ubiquitination and degradation. It collaborates with the anaphase-promoting complex/cyclosome (APC/C) an important E3 ligase complex ensuring the proper progression of the cell cycle especially during the metaphase-anaphase transition. Through this action UBE2C aids in maintaining genomic stability by preventing the accumulation of proteins that can interfere with cell division.
- Pathways
The role of UBE2C is integral in the cell cycle and ubiquitin-proteasome pathways. The enzyme participates in the proper execution of the metaphase-anaphase transition and degradation of cell cycle regulators like cyclin B. UBE2C interacts with proteins such as CDC20 a co-activator of APC/C to ensure accurate coordination of cell division events. Its function in the ubiquitin-proteasome pathway emphasizes its role in maintaining protein homeostasis.
- Associated diseases and disorders
UBE2C's dysfunction or overexpression associates with cancer development and progression. Overexpression of UBE2C has been observed in various cancers including breast cancer and prostate cancer and may contribute to tumorigenesis by disrupting cell cycle control. UBE2C can interact with oncoproteins such as MYC further linking its dysregulation to cancer pathways. Understanding the relationships between UBE2C and cancer may offer insights into therapeutic targets for tumor treatment.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
3 product images
Western blot - Human UBE2C knockout HeLa cell lysate (ab257775)
Lane 1: Wild-type HeLa cell lysate 20 μg
Lane 2: UBE2C knockout HeLa cell lysate 20 μg
Lane 3: WI-38 cell lysate 20 μg
Lane 4: K652 cell lysate 20 μg
Lane 5: SW480 cell lysate 20 μg
Lane 6: CACO2 cell lysate 20 μg
False colour image of Western blot: Anti-UBE2C antibody staining at 1/1000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (Anti-GAPDH antibody [6C5] - Loading Control ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, Anti-UBE2C antibody ab12290 was shown to bind specifically to UBE2C. A band was observed at 20 kDa in wild-type HeLa cell lysates with no signal observed at this size in UBE2C knockout cell line Human UBE2C knockout HeLa cell line ab265032 (knockout cell lysate ab257775). To generate this image, wild-type and UBE2C knockout HeLa cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in fluorescent western blot (TBS-based) blocking solution before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) at 1/20000 dilution.All lanes: Western blot - Anti-UBE2C antibody (Anti-UBE2C antibody ab12290) at 1/1000 dilution
Lane 1: Wild-type HeLa cell lysate at 20 µg
Lane 2: UBE2C knockout HeLa cell lysate at 20 µg
Lane 3: WI-38 cell lysate at 20 µg
Lane 4: K-562 (Human chronic myelogenous leukemia lymphoblast cell line ) whole cell lysate at 20 µg
Lane 5: SW480 cell lysate at 20 µg
Lane 6: CACO2 cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 20 kDa
Observed band size: 20 kDa
Western blot - Human UBE2C knockout HeLa cell lysate (ab257775)
Lane 1: Wild-type HeLa cell lysate 20 μg
Lane 2: UBE2C knockout HeLa cell lysate 20 μg
Lane 3: WI-38 cell lysate 20 μg
Lane 4: K652 cell lysate 20 μg
Lane 5: SW480 cell lysate 20 μg
Lane 6: Caco-2 cell lysate 20 μg
False colour image of Western blot: Anti-UBE2C antibody [EPR23165-31] staining at 1/1000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (Anti-GAPDH antibody [6C5] - Loading Control ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, Anti-UBE2C antibody [EPR23165-31] ab252940 was shown to bind specifically to UBE2C. A band was observed at 20 kDa in wild-type HeLa cell lysates with no signal observed at this size in UBE2C knockout cell line Human UBE2C knockout HeLa cell line ab265032 (knockout cell lysate ab257775). To generate this image, wild-type and UBE2C knockout HeLa cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) at 1/20000 dilution.All lanes: Western blot - Anti-UBE2C antibody [EPR23165-31] (Anti-UBE2C antibody [EPR23165-31] ab252940) at 1/1000 dilution
Lane 1: Wild-type HeLa cell lysate at 20 µg
Lane 2: UBE2C knockout HeLa cell lysate at 20 µg
Lane 3: WI-38 cell lysate at 20 µg
Lane 4: K-562 (Human chronic myelogenous leukemia lymphoblast cell line ) whole cell lysate at 20 µg
Lane 5: SW480 cell lysate at 20 µg
Lane 6: Caco-2 cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 20 kDa
Observed band size: 20 kDa
Sanger Sequencing - Human UBE2C knockout HeLa cell lysate (ab257775)
Homozygous: 1 bp deletion in exon 2
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com